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The aim of present study was to develop and evaluate buccoadhesive Quetiapine Fumarate (QF) tablets, 
which is extensively metabolised by liver. Buccoadhesive tablets of QF were prepared using HPMC 
K4M, HPMC K15M and combination of carbopol and HPC as mucoadhesive polymers by direct 
compression method. Sodium deoxycholate was added to formulation to improve the permeation of 
drug. The formulations were tested for bioadhesion strength, ex vivo residence time, swelling time and 
in vitro dissolution studies and ex vivo permeation studies. Optimized formulation (F3) showed 92% in 
vitro release in 8 h and 67% permeation of drug through porcine buccal mucosa and followed fickian 
release mechanism with zero order kinetics. FTIR studies of optimized formulation showed no evidence 
of interaction between the drug and polymers. In vivo mucoadhesive behaviour of optimized formulation 
was performed and subjective parameters were evaluated.
Uniterms: Quetiapine Fumarate. Bioadhesion. In vivo mucoadhesive behaviour.
O objetivo do presente estudo foi desenvolver e avaliar os comprimidos bucoadesivos de fumarato de 
quetiapina (FQ), que é extensivamente metabolizada no fígado. Os comprimidos bucoadesivos de FQ 
foram preparados utilizando-se HPMC K4M, HPMC K15M e a combinação de carbopol e HPC como 
polímeros mucoadesivos pelo método de compressão direta. O desoxicolato de sódio foi adicionado à 
formulação para melhorar a permeação do fármaco. As formulações foram testadas quanto à força de 
bioadesão, tempo de residência ex vivo, tempo de inchamento, dissolução in vitro e permeação ex vivo. 
A formulação otimizada (F3) mostrou 92% de liberação in vivo em 8 h e 67% de permeação do fármaco 
através da mucosa bucal de porco e seguiu o mecanismo fickiano de liberação com cinética de ordem 
zero. Os estudos de FTIR da formulação otimizada não mostraram evidência da interação entre o 
fármaco e os polímeros. O comportamento mucoadesivo in vivo da formulação otimizada foi efetuado 
e avaliaram-se os parâmetros subjetivos.
Uniterms: Fumarato de quetiapina. Bioadesão. Comportamento mucoadesivo in vivo.
INTRODUCTION
Bioadhesive buccal drug delivery provides an at-
tractive alternative to the oral route of drug administration 
particularly overcoming deficiencies such as high first-
-pass metabolism and drug degradation in the harsh gas-
trointestinal environment (Gibaldi, 1985; Senel, Hincal, 
2001). The stratified squamous epithelium supported by a 
connective tissue lamina of buccal mucosa was targeted as 
a site for drug delivery (Squier, Wertz, 1996). Buccal drug 
delivery provides a number of advantages like robustness 
of epithelium, usage of the dosage form in accordance with 
need, good accessibility and comparatively less suscepti-
bility to enzymatic activity (Shanker et al., 2009) and can 
administer drugs to patient who cannot be dosed orally 
to prevent accidental swallowing (Vamshi Vishnu et al., 
2007). Therefore, adhesive mucosal dosage forms were 
developed for oral delivery, in the form of adhesive tablets 
(Schor et al., 1983; Owens, Dansereau, Sakr, 2005; Akbari 
et al., 2004), adhesive gels (Bremecker, Strempel, Klein, 
1984; Ishida, Vambu, Vagai, 1983; Packer et al., 2001) 
and adhesive patches (Guo, 1994; Anders, Merkle, 1989).
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The major limiting factor for development of Bioad-
hesive buccal delivery devices is the permeation of drug 
through membrane. The main barrier for the absorption of 
drug is the epithelium of the buccal mucosa. To improve 
absorption through buccal mucosa, several approaches 
have been investigated. By changing the physicochemical 
properties of the drug, increased permeation of the drug 
through the buccal membrane and prevention of drug 
degradation by enzyme was achieved (Shojaei, 1998). The 
amount of drug available for absorption was increased by 
improving the bioadhesion and release characteristics of 
buccal delivery (Nagai, Machida, 1985). Addition of per-
meation enhancers is one of the approaches. Substances 
that facilitate the permeation through buccal mucosa are 
referred as permeation enhancers. Incorporation of perme-
ation enhancers improves the delivery of drug via buccal 
membrane, which could reduce barrier properties of the 
buccal epithelium (Aungst, Rogers, 1989; Lee, Yamamoto, 
Kompella, 1991; Pitha, Harman, Michel, 1986; Burnside, 
Keith, Snipes, 1989; Zhang et al., 1994; Steward, Bayley, 
Howes, 1994; Ebert et al., 1994; Hoogstraate et al., 1997).
Quetiapine Fumarate (QF), 2-[2-(4-dibenzo [b, f] 
[1,4]thiazepin-11-yl-1-piperazinyl)ethoxy]-ethanol fuma-
rate (2:1) (salt), is an atypical psychotropic agent belong-
ing to a class dibenzothiazepine derivate. It is used in the 
treatment of schizophrenia and manic episode associated 
with bipolar I disorder (Bhanudas, Sanjay, 2009). The peak 
plasma concentration is reached with in 1.5h. The bioavail-
ability of QF is about 9% and half life is 6 hr and is widely 
distributed through out the body and 83% of drug binds 
to plasma proteins. It is extensively metabolised in liver 
to the sulfoxide metabolite and parent acid metabolite by 
sulfoxidation and oxidation; both metabolites are pharma-
cologically inactive leading to lower bioavailability. So, 
QF is selected as model drug for Bioadhesive buccal drug 
delivery to overcome extensive first-pass metabolism.
The aim of present study was to develop buccoadhe-
sive QF tablets to enhance bioavailability of drug.
MATERIAL AND METHODS
Material
Quetiapine Fumarate (QF) is a gift sample from 
Matrix Laboratories, Hyderabad, India. Hydroxypropyl 
methylcellulose (HPMC K4M, HPMC K15M) and perlitol 
S.D. 200 are gift samples from Dr. Reddy’s Laboratories, 
Hyderabad. Carbopol 934P was purchased from S. D. Fine 
Chem. Ltd., Mumbai, India. Hydroxy propyl cellulose 
(HPC) was donated by Natco Pharma, Hyderabad, India. 
Sodium deoxycholate was purchased from Moly Chem., 
Mumbai, India. All other chemicals and reagents used 
were of analytical grade.
Methods
Solubility studies
Quetiapine Fumarate (QF) solubility studies in phos-
phate buffer, pH 6.6 was determined by phase equilibrium 
method. An excess amount of QF was taken in 20 mL 
vial containing 10 mL of phosphate buffer, pH 6.6. These 
vials were closed with rubber caps and agitated at room 
temperature for 24 h using rotary shaker (Remi Instru-
ments, Mumbai, India). The solution was filtered through 
a 0.2 µm whatman filter paper after 24 h. The amount of 
drug solubilized was estimated by measuring absorbance 
at 250 nm using a UV spectrophotometer (Systronic PC-
Based Double Beam Spectrophotometer 2202, Ahmed-
abad, India) (Gupta, Garg, Khar,1993). The studies were 
repeated in triplicate (n=3) and mean was calculated.
Tissue isolation
Buccal tissue of domestic pork was taken from a lo-
cal slaughter house and was stored in Krebs buffer, pH 7.4 
at 4 °C upon collection. The epithelium was separated 
from the underlying connective tissue with a surgical 
procedure. The membrane was mounted within 24 h of 
isolation of buccal tissue over Franz diffusion cell.
Ex vivo permeation of drug solution
Ex vivo permeation of drug solution through the por-
cine buccal membrane was studied. The buccal epithelium 
was carefully mounted over a Franz diffusion cell with 
an internal diameter of 2.4 cm (4.52 cm2 area) and with a 
receptor compartment volume of 14 mL, It is filled with 
phosphate buffer, pH 6.6. After the buccal membrane was 
equilibrated for 30 min with buffer solution, the receptor 
chamber was filled with fresh phosphate buffer solution 
(pH 6.6) and the donor chamber was charged with (5 mL) 
buffer solution . The entire setup was placed over magnetic 
stirrer (Remi, 2MLH, Mumbai, India) at 50 rpm and tem-
perature was maintained at 37± 0.2 °C. Aliquots samples 
(1 mL) were collected at predetermined intervals up to 
8 h and the amount of drug permeated through the buccal 
mucosa was then determined at 250 nm using UV spec-
trophotometer. The experiment was repeated in triplicate 
(n=3) and mean values were calculated. The cumulative 
amount of the permeated drug was plotted against time. 
The flux (J) and the permeability coefficient (P) were 
calculated by using the following equations (1) and (2).
 J = dQ/dt (1)
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TABLE I - Composition of quetiapine fumarate (QF) buccal tablets
Ingredients F1 F2 F3 F4 F5 F6 F7 F8 F9 F10
API (mg) 25.00 25.00 25.00 25.00 25.00 25.00 25.00 25.00 25.00 25.00
HPMC K4M (mg) 50.00 37.50 25.00 18.75 - - - - - -
HPMC K15M (mg) - - - - 25.00 18.75 12.50 - - -
NaCMC (mg) - - - - - - - - - -
Carbopol (mg) - - - - - - - 10.00 10.00 5.00
HPC (mg) - - - - - - - 40.00 15.00 20.00
Perlitol (mg) 42.00 54.50 67.00 73.25 67.00 73.25 79.50 42.00 67.00 67.00
Magnesium stearate (mg) 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00
Talc (mg) 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00
Aspartame (mg) 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00
Ethyl Cellulose(mg) 30.00 30.00 30.00 30.00 30.00 30.00 30.00 30.00 30.00 30.00
*All the above formulations contains 1 mg of Magnesium stearate, Talc and Aspartame and Total tablet weight is 150 mg.
* API-Active pharmaceutical ingredient, HPMCK4M-Hydroxy Propyl Methyl Cellulose K4M, NaCMC-Sodium Carboxy Methyl 
Cellulose, HPC-Hydroxy Propyl Cellulose, Perlitol as filler.
 P = (dQ/dt) ∆CA  (2)
Where J is flux (mg h−1 cm−2); P is permeability coefficient 
(cm h−1); dQ/dt is the slope obtained from the steady-state 
portion of the curve; ΔC is the concentration difference 
across the mucosa and A is the area of diffusion (cm2).
Buccoadhesive tablet preparation
Buccoadhesive tablets were prepared as shown in 
Table I by direct compression method. Prior to direct 
compression, QF mixed manually with polymers and 
perlitol S. D. 200 as a filler and was screened through 
sieve No. 40 and then lubricants (talc and magnesium 
stearate) were added. Blending for core and backing layer 
was carried out separately. First, the backing layer was 
compressed using 8.0 mm flat faced punches on Cadmach 
rotary tablet machine (Cadmach, Ahmedabad, India). 
Then powder of core layer was added to previously 
obtain backing layer and compressed again (Shanker et 
al., 2009).
Thickness
The thickness of tablets was determined using digital 
caliper (Aerospace, India). Ten individual tablets were 
measured and the average thickness was calculated.
Weight variation
Weight variation test was carried out for ten tablets 
of each batch using an electronic balance (Shimadzu, 
Aux*200, Japan) and average values were calculated.
Hardness
Hardness for three tablets of each batch was mea-
sured by using Monsanto hardness tester and average 
values were calculated.
Assay
Ten tablets were selected randomLy and were pow-
dered in a mortar with pestle; powder equivalent to the 
mass of one tablet was dissolved in methanol by sonica-
tion for 30min and filtered through 0.2 µm whattman filter 
paper. The drug content was analyzed at 250 nm using a 
UV-Visible spectrophotometer. The experiment was car-
ried out in triplicate and mean drug content was calculated.
In vitro bioadhesion studies
Bioadhesion strength of the tablets was determined 
on a modified physical balance (Shanker et al., 2009; 
Gupta, Garg, Khar, 1993). This apparatus consists of a 
modified double beam physical balance in which right 
pan was replaced with a lighter pan and the left pan was 
replaced with a glass slide (4 cm length and 2.5 cm width) 
which was suspended by means of Teflon rings and copper 
wire. The setup was balanced in such a way that it consists 
of 5 g of removable weights on right pan and equivalent 
amount of clay on other side. The height of the total setup 
was adjusted so as to accommodate a glass container of 
6.6 cm height. To find bioadhesion strength, buccal tablet 
was stack to the glass slide with cyanoacrylate adhesive 
and balance was set in to weighing mode with the help of 
a knob that is situated at the base of the balance. Now, 5 g 
of weight on the right pan is removed. This lowered the 
glass slide along with the tablet over the membrane with 
a weight of 5.0 g. The entire setup was kept undisturbed 
for 5 min. Then, the weights on the right-hand side were 
slowly added in increments of 0.1 g until the tablet just 
A. R. Potu, N. Pujari, S. Burra, P. R. Veerareddy338
separated from the membrane surface. The excess weight 
on the right pan, i.e., total weight minus 5 g, was taken as 
a measure of the bioadhesive strength.
Ex vivo residence time
The ex vivo residence time of buccal tablets was 
determined using locally modified USP disintegration 
apparatus (Nakamura et al., 1996). The disintegration 
medium was 800mL phosphate buffer, pH 6.6 maintained 
at 37±0.2 °C. The buccal membrane of porcine was tied to 
the surface of a glass slide vertically attached to the appa-
ratus. One surface of tablet was hydrated using 0.5 mL of 
phosphate buffer, pH 6.6 and then the hydrated surface was 
brought in contact with the mucosal membrane. The glass 
slide was vertically fixed to the apparatus and allowed to 
run in such way that the tablet completely immersed in the 
buffer solution at the lowest point and was out at the high-
est point. The time taken for complete erosion or displace-
ment of the tablet from the mucosal surface was noted. 
The experiments were performed in triplicate (n=3) and 
mean of triplicate was determined (Tanaka et al., 1980).
Surface pH study
The bioadhesive tablet was allowed to swell by 
keeping it in contact with 1mL of distilled water for 2 h 
at room temperature. The pH was measured by bringing 
the pH-meter electrode, in contact with the surface of the 
tablet and allowing it to equilibrate for 1 min (Bottenberg 
et al., 1991).
Moisture absorption
Agar (5%, m/V) was dissolved in hot water and 
transferred into Petri dishes and allowed to solidify. Six 
buccal tablets from each formulation were placed in a 
vacuum oven overnight prior to the study to remove 
moisture, if any, and laminated on one side with a water 
impermeable backing membrane. They were then placed 
on the surface of the agar and incubated at 37 °C for one 
hour. Then the tablets were removed and weighed and the 
percentage of moisture absorption was calculated (Agar-
wal, Mishra, 1999).
In vitro drug release studies
In vitro drug release studies were carried out by us-
ing USP XXIII rotating paddle method. The dissolution 
medium was 500 mL of phosphate buffer pH 6.6 with 0.5% 
SLS at 50 rpm maintained at 37±0.2 °C. The backing layer 
of tablet was attached to the glass slide with cyanoacry-
late adhesive and then it was placed in dissolution vessel. 
Aliquot samples (5 mL) were withdrawn at predetermined 
time intervals and equivalent amount was replaced with 
fresh pre-warmed medium. The samples were filtered 
through whatman filter paper and analyzed at 250 nm us-
ing a UV-Visible spectrophotometer.
Ex vivo permeation of buccal tablets
Ex vivo permeation of QF from buccoadhesive ma-
trix tablet through the porcine buccal membrane was stud-
ied by Franz diffusion cell. The membrane was mounted 
between donor compartment and receptor compartment. 
After the buccal membrane was equilibrated for 30min 
with phosphate buffer, pH 6.6 between both the compart-
ments, receptor compartment was filled with fresh buffer 
solution, pH 6.6. The buccal tablet was placed in the donor 
chamber in such a way that core tablet attaches to the buc-
cal membrane (Vamshi Vishnu, 2007.). Aliquot samples 
(1mL) were withdrawn at predetermined time intervals 
and equivalent amount was replaced with fresh prewarmed 
medium. The samples were filtered through whatman 
filter paper and analyzed at 250 nm using a UV-Visible 
spectrophotometer.
In vivo mucoadhesive performance of buccal tablets
In vivo studies were performed by applying tablets 
to gums of five healthy volunteers (aged 22-26 years) to 
obtain the subjective parameters, the residence time and 
loss of the fragment and the possible production of irrita-
tion or pain. Optimized placebo (F3) tablet was given to 
volunteers and was asked to record the time of application 
and time of displacement of tablet and to collect informa-
tion regarding parameters such as irritancy, comfort, taste, 
dry mouth, salivation and heaviness of the system at the 
place of application. Food intake was avoided from 0.5 h 
before beginning of the study to the end of the study but 
water intake is permitted after the initial 0.5 h (Periolia et 
al., 2004).
FTIR studies
The buccoadhesive tablets (F3) were compressed 
and powdered. The palletized powder, along with KBr, 
was used for FTIR studies. The IR spectra were recorded 
using an IR-spectrophotometer (Perkin Elmer FT-IR, 
Perkin Elmer, USA) for drug (QF), HPMC K4M and 
optimized formulation.
RESULTS AND DISCUSSIONS
Solubility studies
Solubility of QF in the phosphate buffer, pH 6.6 
was conducted and it was found to be 3.4 mg/mL. The 
study was conducted in phosphate buffer, pH 6.6 (Shanker 
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TABLE II - Physico-chemical parameters of quetiapine fumarate buccal tablet
Formulation code Thickness (mm)
Weight Variation 
(mg)
Friability 
(%)
Hardness 
(kg/cm2) %Drug content
F1 2.69±0.020 150.0±0.35 0.08 6.4±0.12 99.66
F2 2.63±0.060 148.1±0.70 0.42 5.2±0.24 101.10
F3 2.51±0.024 152.8±0.25 0.06 7.7±0.10 100.62
F4 2.69±0.015 149.2±0.55 0.28 5.1±10.12 99.63
F5 2.36±0.020 146.0±0.24 0.17 4.8±0.33 101.17
F6 2.64±0.010 155.2±0.70 0.07 6.6±0.10 99.04
F7 2.71±0.030 156.3±0.20 0.31 5.1±0.05 100.39
F8 2.63±0.060 148.1±0.70 0.42 5.2±0.24 101.10
F9 2.61±0.030 157.2±0.50 0.23 4.5±0.05 99.03
F10 2.50±0.035 153.5±0.15 0.04 6.1±0.05 100.43
et al., 2009.). The flux and permeability coefficient of 
drug solution was found to be 0.3855 mg h-1 cm-2 and 
0.01542 cm h-1, respectively.
Thickness, weight variation, hardness, friability 
and assay
The thickness, weight variation, hardness and assay 
of the buccal tablets (Table II) were found to be with in the 
prescribed limits. Hardness of the tablets was ranging from 
4.5 kg cm-2 to 7.7 kg cm-2 as the compression force ad-
justed to meet the requirements of buccal bilayered tablets. 
Thickness of the tablets varied from 2.36 mm to 2.71 mm 
and compared with the theoretical value (2.7 mm). The 
assay values were also within the limits 99.04%-101.17% 
due to the proper blending of the drug and excipients. Fri-
ability of the tablets varied from 0.04 to 0.42% probably 
due to the good binding and compressibility of the selected 
excipients and drug.
In vitro bioadhesion studies
The bioadhesion strength, ex vivo residence time 
and surface pH of all formulation were given in Table III. 
Longer and Robinson (Longer, Robinson, 1986) defined the 
term bioadhesion as the attachment of a synthetic or natu-
ral macromolecule to mucus and/or an epithelial surface. 
Mucoadhesion takes place in four major stages: wetting, 
interpenetration, adsorption and formation of secondary 
chemical bonds between mucus membrane and polymer. 
The factors like molecular weight of the polymer, contact 
time with membrane, degree of swelling of the polymer 
and the type of biological membranes used in the study 
affect the strength of mucoadhesion (Park, Robinson, 
1987). The maximum (41.1 mj) and minimum bioadhesion 
strength (17.2 mj) was found in the formulation F8 and F4, 
respectively. The bioadhesion strength increased as the 
polymer concentration increased (Vamshi Vishnu et al., 
2007). The order of bioadhesion was HPMC K4M >HPMC 
K15M>Carbopol. Formulations containing HPMC K15M 
and carbopol showed stronger bioadhesion strength than 
formulation containing HPMC K4M. Very strong bioad-
hesion could damage the epithelia of the buccal mucosa 
(Vamshi Vishnu et al., 2007). Carbopol 934 is reported to 
be responsible for the formation of the hydrogen bonds be-
tween the mucus and functional groups of the polymer. HPC 
was used to provide adhesion and controlled drug release.
Ex vivo residence time
The bioadhesion strength, ex vivo residence time 
and surface pH of all formulation were given in Table III. 
The minimum and maximum ex vivo residence time were 
found to be 4.05 h and 7.70 h, respectively. The optimized 
formulation (F3) showed ex vivo residence time of 5.15h. 
As the polymer concentration increased, bioadhesion 
strength and ex vivo residence time increased (Vamshi 
Vishnu et al., 2007).
Surface pH study
The bio-adhesion strength, ex vivo residence time 
and surface pH of all formulation were given in Table III. 
In order to know the irritation potential in vivo, surface pH 
study was performed because acidic or alkaline pH may 
cause irritation to the mucosa. Surface pH of the optimized 
formulation F3 was found to be 7.18 (near to alkaline pH) 
suggesting that it do not cause any irritation to the mucosa.
Moisture absorption
The moisture absorption studies of tablets give an 
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TABLE III - The bioadhesive strength, residence time, surface pH and moisture absorbed values of quetiapine fumarate tablets
Formulation code Bio adhesion Strength (gm)
Ex vivo residence 
time(hr)
Surface pH Moisture absorbed 
(%)
F1 27.0±0.24 6.14±0.23 7.05±0.070 29.6±1.2
F2 20.6±0.34 5.70±0.16 5.91±0.010 30.3±3.5
F3 19.8±0.04 5.15±0.20 7.18±0.085 32.2±1.4
F4 17.2±0.19 4.05±0.25 6.21±0.015 43.±2.7
F5 29.3±0.06 6.74±0.14 6.81±0.035 31.5±1.6
F6 25.5±0.07 6.26±0.31 6.85±0.015 36.9±0.9
F7 21.0±0.21 5.15±0.35 6.13±0.010 47.8±1.9
F8 41.1±0.27 7.70±0.15 6.92±0.015 52.3±2.6
F9 40.8±0.07 7.03±0.25 6.85±0.030 68.1±1.5
F10 37.0±0.18 6.25±0.35 6.63±0.050 71.7±2.9
indication of the relative moisture absorption capacities 
of polymers and whether the formulations would maintain 
their integrity after moisture absorption. The order of in-
creasing moisture absorption was HPMC K4M < HPMC 
K15M < Carbopol 934 (Table III). The higher moisture 
absorption of Carbopol 934 may be due its predominant 
hydrophilic nature.
In vitro drug release studies
The in vitro drug release profiles of all formulations 
were shown in Figure 1. The drug release from bucco-
adhesive tablets observed to be varied according to the 
type and ratio of matrix forming polymers. Formulations 
F3 and F7 showed burst release which was due to lower 
concentration of HPMC K4M and HPMC K15M. An 
increase in polymer concentration resulted in an increase 
in the viscosity of the gel and creates thick gel barrier 
with longer diffusional path length leading to decrease in 
diffusion coefficient of the drug and hence a reduction in 
cumulative percentage of drug release (F5 and F6). Tablets 
containing lower concentration of either HPMC K4M, 
HPMC K15M or carbopol 934P respectively have shown 
a tendency to release the drug in shorter time periods, 
while the release slowed down as the concentration of the 
polymer increased.
Formulation F3 (91.7 ± 0.51%) composed of 1:1 
FIGURE 1 - Mathematical model fitting of in vitro drug release.
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drug: HPMC K4M ratio; F6 (87.1 ± 1.84%) 1:0.75 drug: 
HPMC K15M ratio and F10 (93.4 ± 3.06%) containing 
carbopol 934P (5mg) and HPC (20mg) showed maxi-
mum release among their respective series. Optimized 
formulation (F3) was containing the less quantity (25 mg) 
of HPMC K4M, and achieved the required bio adhesive 
and other properties required for buccal tablets compared 
to rest of the formulations. Hence, it was selected as op-
timized formulation. F4 and F7 formulations containing 
1:0.75 drug: HPMC K4M and 1:0.5 drug: HPMC K15M 
disintegrated with in 4 hrs because of low concentration 
of polymer. Increasing the concentration of the polymer in 
the formulations showed a sustained effect on QF release. 
The rapidly hydrating polymer dominated in controlling 
the release of QF from the buccal tablets, as seen from the 
dissolution profiles and moisture absorption data. Release 
rates slowed down when the concentration of HPMC 
K4M or HPMC K15M or Carbopol 934P increased from 
1:1 to 1:2 ratios and 1:0.5 to 1:1 in F1-4, F8-10 and F5-7, 
respectively. This is because as the proportion of these 
polymers in the matrix increased, there was an increase 
in the amount of water uptake and proportionally greater 
swelling leading to a thicker gel layer.
Mathematical model fitting of in vitro drug release
The in vitro percentage drug release of optimized 
formulation F3 was attempted to fit into mathematical 
models. The n and R2 values for zero-order, first-order 
and Higuchi and Peppas (Costa, Sousa Lobo, 2001) were 
represented in Table IV. The Peppas model is widely used, 
when the release mechanism is not well known and when 
more than one type of release is involved (Peppas,1985). 
The semiempirical equation is shown as Eq. 3:
 Mt/M∞ = ktn (3)
Where Mt/M∞ is fraction of the drug released at time 
t; k represents a constant, incorporating structural and 
geometrical characteristics of the buccal devices; and n 
is the diffusion exponent, which characterizes the type 
of release mechanism during the dissolution process. For 
non-Fickian release, the value of n falls between 0.5 and 
1.0, while in case of Fickian diffusion, n=0.5; for zero 
TABLE IV - Release kinetics and mechanism of optimized formulation
Formulation code
Mathematical models(Kinetics)
Zero order First order Higuchi Peppas model
F3
R2 R2 R2 n R2
0.9988 0.9950 0.9913 0.398 0.9965
order release (case II transport), n=1; and for supercase 
II transport, n is greater than 1. Observation of all the R2 
values indicated that the highest R2 (0.9988) value was 
found for Zero order release. According to ‘n’ value it 
is less than 0.5, so it follows fickian diffusion with zero 
order release.
Ex vivo permeation of buccal tablets
Based on in vitro drug release studies and the results 
obtained therein and bioadhesion strength of all formula-
tions, formulation F3 was selected for ex vivo permeation 
study. Porcine buccal mucosa resembles that of the human 
in terms of structure and composition. Hence, porcine buc-
cal mucosa was selected for study. The flux, permeability 
coefficient and cumulative drug permeated from formu-
lation F3 with enhancer were found to 0.398 mg h-1 cm-2, 
0.015528 cm/h and 67.2±0.4% respectively. The flux, 
permeability coefficient for drug solution and formula-
tion F3 with sodium deoxycholate enhancer and without 
enhancer were shown in Table V. Presence of enhancer 
(sodium deoxycholate) increases the diffusivity of the 
drug via transcellular and paracellular routes. This is 
due to extraction of lipids from the cell membrane along 
with the extraction of mucosal lipid from the intercellular 
spaces by the formation of micelles (Hoogstraate et al., 
1997.) and causing uncoiling and extension of the protein 
helices leading to opening of the polar pathways for diffu-
sion. All these effects increase the permeation of the drug. 
Cumulative percentage drug permeated of F3 formulation 
was shown in Figure 2.
Porcine buccal mucosa resembles that of the hu-
man in terms of structure and composition. Hence, 
TABLE V - Flux and Permeability coefficient values of drug 
solution and formulation
Formulation code Flux (mg h-1 cm-2)
permeability 
coefficient (cm/h)
Drug solution 0.385 0.01542
F3 without enhancer 0.326 0.01305
F3 with enhancer 0.398 0.015528
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porcine buccal mucosa was selected for the study. The 
flux, permeability coefficient and cumulative drug per-
meated from formulation F3 with enhancer were found 
to 0.398 mg h-1 cm-2, 0.015528 cm/h and 67.2±0.4%, 
respectively. The flux, permeability coefficient for drug 
solution and formulation F3 with enhancer and without 
enhancer were shown in Table V. Presence of enhancer 
(sodium deoxycholate) increases the diffusivity of the 
drug via transcellular and paracellular routes. This is due 
to the extraction of lipids from the cell membrane along 
with the extraction of mucosal lipids as a result of forma-
tion of micelles (Hoogstraate et al.,1997.) and causing 
uncoiling and extension of the protein helices leading to 
opening of the polar pathways for diffusion. All these ef-
fects collectively contributed in enhancing the permeation 
of the drug. Cumulative percentage of drug permeated of 
F3 formulation was shown in Figure 2.
In vivo mucoadhesive performance of buccal tablets
The results of volunteers to each subjective pa-
rameter was shown in Table VI. From the study, it was 
observed that slight bitter taste was perceived at 4h due 
to higher swelling of polymer which is responsible for 
increased thickness of the buccal tablet and this led to 
improved radial release of QF. This radial release might 
be responsible for slight bitter taste.
FTIR studies
FTIR spectra of Quetiapine Fumarate (Figure 3 
A) showed peaks of 3310, 2941, 1741, 1597, 1371 and 
TABLE VI - Response of Healthy Human Male Volunteers to 
Various Subjective Parameters (n=3)
S. NO. Criteria Volunteer’s 
response (%)
1 Irritation  
 None 100
 Slight -
 Moderate -
 Severe -
2 Taste
 Normal 85
 Slightly 15
 Very unpleasant -
 Pleasant -
3 Comfort
 Very comfortable -
 Comfortable 90
 Slightly uncomfortable 10
 Moderately uncomfortable -
 Severely uncomfortable -
4 Dryness of mouth
 None 85
 Slight 15
 Moderate -
 Severe -
5 Salivary secretion
 None 30
 Slight 50
 Moderate 20
 Severe -
6 Heaviness at the place of 
attachment
 None 95
 Slight 5
 Moderate -
 Severe -
7 Dislodgement of the system 
during study
 No 100
 Yes -
FIGURE 2 – In vitro Drug Release of Optimized formulation 
with Enhancer, Without Enhancer and Drug Solution.
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FIGURE 3 - FTIR spectra of A) Drug (quetiapine fumarate), B) Polymer (HPMC K4M), C) Optimized formulation.
1070 cm-1 due to –OH stretching, C-H stretching, C=O 
stretching, N-H bending, C-H bend in plane and C-C 
stretching respectively.
FTIR Spectra of HPMC K4M (Figure 3 B) showed 
peaks of 3283, 1446, 1407, 1248, 951 and 872 cm-1 due 
to C-H stretching, O-H stretching and C-C stretching 
respectively.
FTIR spectra of optimized formulation (Figure 3 C) 
showed both characteristics peaks of drug and polymer 
indicating no drug-polymer interaction.
CONCLUSION
The present work was aimed at developing a buc-
coadhesive Quetiapine Fumarate tablets. Progressive 
hydration technology was employed by using various 
grades of HPMC in combination with carbopol and HPC 
for their reported buccoadhesive and release rate control-
ling abilities. Directly compressed optimized formulation 
F3 containing HPMC K4M in a drug: polymer ratio (1:1) 
showed good bioadhesive strength, 91.5% in vitro drug 
release in 8 hours and 85% permeation through porcine 
buccal mucosa. These findings suggested that buccoad-
hesive tablets of Quetiapine Fumarate tablets could be 
prepared by employing direct compression method and 
improvement in drug permeation through buccal mucosa 
contributing to significant improvement in oral bio avail-
ability of the drug.
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